Literature DB >> 1808619

The stereospecific determination of fluoxetine and norfluoxetine enantiomers in human plasma by high-pressure liquid chromatography (HPLC) with fluorescence detection.

A L Peyton1, R Carpenter, K Rutkowski.   

Abstract

A quantitative method for the simultaneous HPLC resolution and detection of the enantiomers of (R,S) fluoxetine (F) and their metabolites (R,S) norfluoxetine (N) in human plasma has been developed. F is a serotonin uptake inhibitor used in the treatment of depression and is administered as a racemate. After liquid-liquid extraction and derivatization with (R) napthyl ethyl isocyanate (NEI), the separation and detection of the resultant diasteriomers were achieved using normal phase HPLC and fluorescence. The four NEI diastereomers and the internal standard [(-)-N-methyl-gamma-(2-methylphenoxy) benzenepropanamine hydrochloride], representing the enantiomers S-F, R-F, S-N, and R-N were resolved within 15 min. The assay for each analyte was linear using two concentration ranges of 1-10 and 10-500 ng/ml of human plasma. The precision and accuracy are reported as the coefficient of variation (%CV) and relative error (%RE). The sum of the chiral HPLC results from plasma samples were compared to the achiral gas chromatographic/electron capture (GC/EC) results. The correlation between these two methods, for total F and N, resulted in r2 values of 0.98 and 0.89, respectively. The chiral HPLC method is currently being applied to clinical studies for the evaluation of the enantiomeric disposition of F.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1808619     DOI: 10.1023/a:1015802702064

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  4 in total

1.  Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography.

Authors:  S H Wong; S S Dellafera; R Fernandes; H Kranzler
Journal:  J Chromatogr       Date:  1990-01-19

2.  Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection.

Authors:  J F Nash; R J Bopp; R H Carmichael; K Z Farid; L Lemberger
Journal:  Clin Chem       Date:  1982-10       Impact factor: 8.327

3.  Pharmacologic effects in man of a specific serotonin-reuptake inhibitor.

Authors:  L Lemberger; H Rowe; R Carmichael; S Oldham; J S Horng; F P Bymaster; D T Wong
Journal:  Science       Date:  1978-01-27       Impact factor: 47.728

Review 4.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; R C Heel; S P Lewis
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

  4 in total
  3 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  Simultaneous RP-HPLC and HPTLC Estimation of Fluoxetine Hydrochloride and Olanzapine in Tablet Dosage Forms.

Authors:  Sejal Patel; N J Patel
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.